Avacta Group Plc engages in research and development activities within the therapeutics business, focusing on the development of cancer drugs and in vitro diagnostics in the United Kingdom, France, North America, South Korea, the rest of Europe, and internationally. The company operates through the Therapeutics segment. It provides its proprietary Affimer and pre|CISION technology platforms, which are used to deliver a portfolio of differentiated therapeutic and diagnostic products that address various markets. The company is developing AVA6000, a peptide drug conjugate form of doxorubicin, which is in Phase I clinical trials for treating locally advanced or metastatic solid tumors; AVA6103, a peptide drug conjugate technology designed to deliver exatecan, a potent topoisomerase I inhibitor, directly to tumors while limiting the exposure of the released exatecan in normal tissues; and AVA7100, which is designed to drive localization to FAP-expressing tumors, with the second Affimer domain binding albumin to improve pharmacokinetics by increasing plasma half-life. The company has a collaboration agreement with LG Chem for developing and commercializing Affimer-based therapeutics. Avacta Group Plc was incorporated in 2003 and is headquartered in London, United Kingdom.